<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri",sans-serif;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:590315053;
mso-list-template-ids:-958249742;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:1604993828;
mso-list-type:hybrid;
mso-list-template-ids:-160677430 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.macfound.org_programs_100change_&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=GJIJdwXQBlRNmEp2Vr00XmzerQ0K4dPoJoupypOjuVE&s=wyl2nV4mWVIMTb8f4NmC4q_xQLRjYoVdw8Vr76eZOEQ&e="><span style="color:#0563C1">MacArthur Foundation: 100&Change</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Some problems cannot be solved by grants of the size that foundations typically provide. By funding at a level far above what is typical in philanthropy, we can address problems and support
solutions that are radically different in scale, scope, and complexity. <b>$100 million</b> is a large enough sum to focus on a serious problem and its solution in a meaningful and lasting way. We hope that <i>100&Change</i> can inspire a conversation about
solutions and about how we can solve some of our most significant problems. We recognize that we do not know it all and designed <i>100&Change</i> to be agnostic with respect to field or problem area. We seek proposals that articulate both a problem and its
solution. <b>Competitive proposals will address a significant problem and provide a solution that is impactful, evidence-based, feasible, and durable.<o:p></o:p></b></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Proposals due in August 2019.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.michaeljfox.org_research_grant-2Ddetail.php-3Fid-3D28&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=GJIJdwXQBlRNmEp2Vr00XmzerQ0K4dPoJoupypOjuVE&s=ZFwMyW-xmdb6Dpt-yuTaS-w_aPVYQXi99lRkUjYeVo4&e=" target="_blank"><span style="color:#0563C1">Michael J. Fox Foundation: Therapeutic Pipeline Program</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Therapeutic Pipeline Program at the Michael J. Fox Foundation for Parkinson’s Research is focused on advancing the development of Parkinson’s disease therapies and interventions along
the pre-clinical and clinical path (i.e., both drug and non-pharmacological therapeutics, including gene therapy, biological, surgical and non-invasive approaches). To that end, MJFF is inviting proposals for research with the potential for fundamentally altering
disease course and/or significantly improving treatment of symptoms above and beyond current standards of care.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The program is open to industry and academic investigators proposing novel approaches or repositioning approved or clinically safe therapies from non-PD indications in three areas:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo1"><b><span style="font-size:12.0pt;font-family:Palatino">Applied Technologies as Treatments for Parkinson’s</span></b><span style="font-size:12.0pt;font-family:Palatino"> -- The use of innovative technologies
(e.g., assistive devices, wearable technologies) is an emerging and rapidly developing area offering new treatment opportunities for those with PD. Proposals should focus on testing the efficacy of novel devices and technologies designed to address critical,
poorly managed symptoms of Parkinson’s disease. The foundation is particularly interested in: proof-of-concept efficacy and/or feasibility studies from prototype or available devices and technologies; and analysis of existing clinical data sets from studies
of applied technologies for evidence of clinical impact in people with PD.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo1"><b><span style="font-size:12.0pt;font-family:Palatino">Disease-Modifying Strategies</span></b><span style="font-size:12.0pt;font-family:Palatino"> -- The goal of the proposed research should be to protect
or restore degenerating and/or dysfunctional neurons affected in PD. Proposals may target any of the following (though investigators are not restricted to this list): alpha-synuclein; GBA; inflammation; LRRK2; mitochondrial function; protein folding.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo1"><b><span style="font-size:12.0pt;font-family:Palatino">Symptomatic Strategies</span></b><span style="font-size:12.0pt;font-family:Palatino"> -- The goal of the proposed research should be to significantly
improve treatment of symptoms above and beyond current standards of care. Proposals may aim to achieve any of the following: alleviate motor symptoms of PD; alleviate non-motor symptoms of PD; and/or reduce complications and side effects of current PD treatments.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">All proposals must have a well-defined plan for moving toward clinical utility for Parkinson’s disease (PD) patients. The foundation anticipates awarding one- to two-year grants of up
to $500,000 for pre-clinical or applied technology programs, and one- to two-year grants of up to $2 million for clinical programs.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Pre-proposals due April 19, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: April 5.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.pfizer.com_files_TTRAmyloidosisResearch-5FCompetitiveGrantProgram-5F2019US.pdf&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=GJIJdwXQBlRNmEp2Vr00XmzerQ0K4dPoJoupypOjuVE&s=FW4nY83Ndx9UgJ80JCS1_CnA6zKp6qPbMAK2WfVjcbY&e="><span style="color:#0563C1">Pfizer Competitive Grant Program for Transthyretin Amyloidosis
(ATTR) including cardiomyopathy, peripheral neuropathy, and mixed phenotypes</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this competition is to improve the care of patients with ATTR by improving our understanding of disease epidemiology, pathophysiology, early diagnosis, prognosis, and emerging
treatment paradigms. Individual projects requesting up to $75,000 will be considered. Pfizer anticipates awarding up to four grants.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due May 3, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: April 19.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.floridablue.com_foundation_improve-2Dconsumer-2Dhealth-2Dchildhood-2Dobesity&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=GJIJdwXQBlRNmEp2Vr00XmzerQ0K4dPoJoupypOjuVE&s=GdVm5Y7kbKkjvwrFSnVBfuCEjvHs3dIi3OHGVI4foGo&e="><span style="color:#0563C1">Florida Blue Foundation: Consumer Health</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The intent of the Consumer Health Focus Area is to award grants to nonprofit organizations that can provide resources, information and programs designed to make it easier for
underserved, underinsured or low-income individuals in Florida to find current and reliable health care services to manage their own health and well-being.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The 2019 Funding Priorities are:<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Funding Priority #1: Mental Health:</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"> Preventive and education programs designed to assist underserved,
underinsured or low-income individuals in Florida to improve their mental health.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Funding Area #2: Health Literacy:</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"> Programs designed to assist underserved, underinsured or low-income
individuals in Florida acquire the skills and capabilities needed to understand basic health information and the impact their choices have on their own health.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">Applications can be submitted for one or both of the Funding Priorities. Organizations applying for both
<u>must</u> complete a separate application for each Funding Area.<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">The Florida Blue Foundation has approximately $3.5 million for the funding of this program.<o:p></o:p></span></li><li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">The Foundation will fund three-year and four-year grants. The average amount per grant is from $80,000 - $100,000 per year.<o:p></o:p></span></li><li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Priority will be given to applicants that include collaborations and partnerships with other organizations in Florida.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due May 20, 2019.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: May 6.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:red"><a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__earlychildhoodfoundation.org_&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=GJIJdwXQBlRNmEp2Vr00XmzerQ0K4dPoJoupypOjuVE&s=gc0tfJ23AH_r83jh9J-F62M3ngFZDY80iRQ7CLlZRBE&e=" target="_blank"><span style="color:#0563C1">Caplan Foundation for Early Childhood Grants</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The Caplan Foundation for Early Childhood supports innovative projects and programs with the potential to significantly enhance the development, health, safety, education,
and/or quality of life of children from infancy through five years of age. To that end, the foundation provides funding in the areas of early childhood welfare, early childhood education and play, and parenting education.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">1) Early Childhood Welfare: Children can only reach their full potential when all aspects of their development — intellectual, emotional and physical — are supported. Providing
a safe and nurturing environment for infants and preschoolers is essential, as is imparting to them the skills of living in a culturally diverse world. To that end, the foundation supports programs that research best child-rearing practices and identify models
that can provide creative, caring environments in which all can children thrive.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">2) Early Childhood Education and Play: Research shows that children need to be stimulated as well as nurtured early in life if they are to succeed in school, work, and life.
That preparation relates to every aspect of a child’s development, and everywhere a child learns — at home, in childcare settings and in preschool. The foundation seeks to improve the quality of both early childhood teaching and learning through the development
of innovative curricula and research based pedagogical standards, as well as the design of imaginative play materials and learning environments.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">3) Parenting Education: To help parents create nurturing environments for their children, the foundation supports programs that teach parents about developmental psychology,
cultural child-rearing differences, pedagogy, issues of health, prenatal care, and diet, as well programs that provide both cognitive and emotional support to parents.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Letter of intent due May 31, 2019.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: May 17.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:red"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.vilcek.org_prizes_creative-2Dpromise_biomedical-2Dscience.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=GJIJdwXQBlRNmEp2Vr00XmzerQ0K4dPoJoupypOjuVE&s=uOSMfVQIr_4wZypggdOmRowI9nNGONs8wicVyXHtmtU&e=" target="_blank"><span style="color:#0563C1">Overview</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The Vilcek Foundation will award three prizes of $50,000 each (unrestricted) to
<b>young (age 38 and under) foreign-born</b> biomedical scientists who demonstrate outstanding early achievement. Eligible work may be in
<b>basic, applied, and/or translational biomedical science</b>.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due June 10, 2019.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: May 28.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:red"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D214.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=GJIJdwXQBlRNmEp2Vr00XmzerQ0K4dPoJoupypOjuVE&s=3SkapUaCu1HoEceGddzJTylKfs9ZgGRJoJAYHcxrMJc&e=" target="_blank"><span style="color:#0563C1">Novel Assays to Address Translational Gaps in Treatment Development
(UG3/UH3 Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The overall goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The funding opportunity announcement
(FOA) will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative
will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance
between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic
development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The objectives of the FOA will be accomplished by supporting partnerships among basic and translational neuroscientists who are committed to advancing the discovery of
<i>in vivo</i> physiological measures as tools for target validation and therapeutic development. Groups will be tasked with developing and optimizing
<i>in vivo</i> assays of brain processes in both animals and in healthy humans. Groups will evaluate assay performance across both species in response to specific chemical, physiological, or behavioral manipulations. In this way, projects will reveal the potential
of specific assays to translate from animals to humans, suggesting assays for further development as tools in the treatment development pipeline.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due June 20, 2019; October 18, 2019; February 20, 2020; June 19, 2020; October 20, 2020; February 19, 2021; June 21, 2021; October 20, 2021; and February 21, 2022.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for June deadline: June 6.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Behavioral & Integrative Treatment Development Program (R34 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_par-2D19-2D213.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=GJIJdwXQBlRNmEp2Vr00XmzerQ0K4dPoJoupypOjuVE&s=pm0bRySgK2oF6G6U1ViNQgkIOqJin0f-ez24Lbh2pXI&e=" target="_blank"><span style="color:#0563C1">R34</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D212.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=GJIJdwXQBlRNmEp2Vr00XmzerQ0K4dPoJoupypOjuVE&s=HuftxQrcYe7idfRU878JpFt_4IdYwILmbWC1_GIpZ7c&e=" target="_blank"><span style="color:#0563C1">R01</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these funding opportunity announcements is to encourage behavioral intervention development research. Specifically, test efficacy, conduct clinical trials, examine mechanisms
of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological treatments. Research of interest includes but is not limited to Stage II
and Stage III efficacy research, including: (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize
technologies to boost effects and increase implementability and sustainability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment,
HIV and addiction medications; and (6) interventions to treat substance misuse and chronic pain.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 23, 2019; March 23, 2020; July 23, 2020; March 23, 2021; July 23, 2021; and March 23, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for July deadline: July 9.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">To search for additional funding opportunities, please visit <a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e="><span style="color:#0563C1">CoM’s
unofficial funding opportunities blog</span></a>.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><o:p> </o:p></p>
</div>
</body>
</html>